Disposition of patients with chronic ITP treated with romiplostim for up to 156 weeks. One patient did not receive romiplostim because he withdrew consent. The adverse events leading to discontinuation from the study were increased bone marrow reticulin in 2 patients, vaginal hemorrhage, musculoskeletal pain and headache, deep vein thrombosis, septic thrombophlebitis, and monoclonal gammopathy of undetermined significance in 1 patient each. “Other” reasons for discontinuation were lack of response to romiplostim (2), possible ITP remission/cure (2), patient request (1), and unsteady platelet count (1).